A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita

Bone Marrow Transplantation

Volumn 47, Issue 9, 2012, Pages 1254-1255

  Kharfan Dabaja, M A ^a   Otrock, Z K ^a   Bacigalupo, A ^b   Mahfouz, R A ^a   Geara, F ^a   Bazarbachi, A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VALINE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; BONE MARROW BIOPSY; BRONCHIOLITIS OBLITERANS; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSKERATOSIS CONGENITA; ESOPHAGUS VARICES; FEBRILE NEUTROPENIA; GROWTH RETARDATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; LETTER; LIVER ATROPHY; LIVER CIRRHOSIS; LIVER HYPERTROPHY; MALE; MUTATIONAL ANALYSIS; NAIL DYSTROPHY; PANCYTOPENIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLENOMEGALY; TELANGIECTASIA; THORAX RADIOGRAPHY; THROMBOCYTE TRANSFUSION; TONGUE ULCER; TREATMENT RESPONSE;

ADULT; ANTILYMPHOCYTE SERUM; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DYSKERATOSIS CONGENITA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; TRANSPLANTATION CONDITIONING; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 84866004422     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.257     Document Type: Letter

References (10)

1. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am 2009; 23: 215-231.
2. Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389-392. (Pubitemid 27096073)
3. Rocha V, Devergie A, Socié G, Ribaud P, Espérou H, Parquet N et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243-248. (Pubitemid 28470826)
4. Langston AA, Sanders JE, Deeg HJ, Crawford SW, Anasetti C, Sullivan KM et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758-765. (Pubitemid 26076778)
5. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011; 46: 98-104.
6. Dror Y, Freedman MH, Leaker M, Verbeek J, Armstrong CA, Saunders FE et al. Lowintensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 847-850. (Pubitemid 36675739)
7. Ayas M, Al-Musa A, Al-Jefri A, Al-Seraihi A, Al-Mahr M, Rifai S et al. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin. Pediatr Blood Cancer 2007; 49: 103-104. (Pubitemid 46847077)
8. Bacigalupo A, Socié G, Lanino E, Prete A, Locatelli F, Locasciulli A et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 2010; 95: 976-982.
9. MacMillan ML, Blazar BR, DeFor T, Ma L, Tolar J, Zierhut H et al. Alternate donor HCT for fanconi anemia (FA): results of a total body irradiation (TBI) dose de-escalation study. Blood (ASH Annu Meet Abstr) 2008; 112 abstract no. 2998.
10. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369. (Pubitemid 34627202)